Name | International Biotech Trust |
---|---|
Epic | IBT |
Isin | GB0004559349 |
Index | MID300 |
Industry | Closed End Investments |
Latest share price | 710.00p | Net gearing | n/a |
---|---|---|---|
Market capitalisation | £258.46 | Debt ratio | n/a |
Shares in issue | 37.38 | Debt-to-equity ratio | n/a |
P/E ratio | n/a | Assets / equity ratio | n/a |
Total dividends per share | 13.90p | Price to book value | n/a |
Dividend yield | 4.4 | ROCE | n/a |
Dividend cover | -0.34 | EPS growth | n/a |
Earning per share | -9.53 | 52-week high / low | 556.00p / 718.00p |
Type | Ex-date | Pay-date | Net-dividend |
---|---|---|---|
1st Interim | 2023-12-21 | 2024-01-26 | 13.90p |
2nd Interim | 2023-07-27 | 2023-08-25 | 14.20p |
1st Interim | 2022-12-29 | 2023-01-27 | 14.00p |
2nd Interim | 2022-08-04 | 2022-08-26 | 15.70p |
1st Interim | 2021-12-30 | 2022-01-28 | 15.70p |
2nd Interim | 2021-07-15 | 2021-08-27 | 14.20p |
1st Interim | 2020-12-24 | 2021-01-29 | 14.20p |
2nd Interim | 2020-07-16 | 2020-08-28 | 12.40p |
Interim | 2019-12-19 | 2020-01-31 | 12.40p |
Company name | International Biotech Trust |
---|---|
Address | 6th Floor, 65 Gresham Street, London, England, United Kingdom, EC2V 7NQ |
Telephone | +44 (0)333 300 1950 |
Website | http://www.internationalbiotrust.com/ |
Director | Position |
---|---|
Ms Gillian Elcock | Non-Executive Director |
Ms Katherine Cornish-Bowden | Non-Executive Chairman |
Mr Patrick Magee | Independent Non-Executive Director |
Ms Caroline Gulliver | Independent Non-Executive Director |
Mr Patrick Maxwell | Independent Non-Executive Director |
Assets £ (m) | 2023 | 2022 | 2021 |
---|---|---|---|
Reporting date | 31/08/23 | 31/08/22 | 31/08/21 |
Intangible asssets and goodwill | n/a | n/a | n/a |
Investments and other non-current assets | 301.9 | 313.43 | 345.34 |
Total non-current assets | 301.9 | 313.43 | 345.34 |
Inventory / work in progress | n/a | n/a | n/a |
Trade and other receivables | 2.97 | 13.49 | 0.94 |
Cash and equivalents | n/a | n/a | 1.56 |
Other current assets and asset held for resale | n/a | n/a | n/a |
Total of all assets | 304.87 | 326.92 | 347.83 |
Liabilities £ (m) | 2023 | 2022 | 2021 |
---|---|---|---|
Short term liabilities | 34.55 | 42.03 | 24.06 |
Long term liabilities | n/a | n/a | n/a |
Other liabilites / pension etc | n/a | n/a | n/a |
Total of all liabilities | 34.55 | 42.03 | 24.06 |
Net assets £ (m) | 2023 | 2022 | 2021 |
---|---|---|---|
Net assets | 270.32 | 284.89 | 323.77 |
Equity £ (m) | 2023 | 2022 | 2021 |
---|---|---|---|
Share capital | 10.35 | 10.35 | 10.35 |
Minority interests | n/a | n/a | n/a |
Retained earnings | -50.53 | -46.66 | -43.73 |
Share premium account | 29.87 | 29.87 | 29.87 |
Total equity | 270.32 | 284.89 | 323.77 |
Income £ (m) | 2023 | 2022 | 2021 |
---|---|---|---|
Turnover | n/a | n/a | n/a |
Operating profit | -2.51 | -2.11 | -2.37 |
Pre-tax profit | -3.75 | -2.78 | -2.59 |